CME/CE

This MinuteCE series examines practical approaches to hyperkalemia management in patients with chronic kidney disease (CKD), heart failure, diabetes, and other cardiorenal comorbidities. Through expert lectures, interviews, and case-based discussions, faculty review guideline-based strategies for managing hyperkalemia while maintaining or optimizing renin-angiotensin-aldosterone system inhibitor (RAASi) and mineralocorticoid receptor antagonist (MRA) therapy. The series compares oral potassium binders by mechanism of action, onset, tolerability, drug-interaction considerations, and sodium- or volume-related concerns. Faculty also address potassium monitoring, recurrent hyperkalemia, and factors that may influence treatment selection, including edema, CKD severity, diabetes, and concomitant therapies. Evidence from DIAMOND and relevant cardiology and nephrology guidelines is incorporated to support informed potassium binder selection and preservation of kidney- and cardiovascular-protective therapy.

This MinuteCE series examines practical approaches to hyperkalemia management in patients with chronic kidney disease (CKD), heart failure, diabetes, and other cardiorenal comorbidities. Through expert lectures, interviews, and case-based discussions, faculty review guideline-based strategies for managing hyperkalemia while maintaining or optimizing renin-angiotensin-aldosterone system inhibitor (RAASi) and mineralocorticoid receptor antagonist (MRA) therapy. The series compares oral potassium binders by mechanism of action, onset, tolerability, drug-interaction considerations, and sodium- or volume-related concerns. Faculty also address potassium monitoring, recurrent hyperkalemia, and factors that may influence treatment selection, including edema, CKD severity, diabetes, and concomitant therapies. Evidence from DIAMOND and relevant cardiology and nephrology guidelines is incorporated to support informed potassium binder selection and preservation of kidney- and cardiovascular-protective therapy.

This MinuteCE series examines practical approaches to hyperkalemia management in patients with chronic kidney disease (CKD), heart failure, diabetes, and other cardiorenal comorbidities. Through expert lectures, interviews, and case-based discussions, faculty review guideline-based strategies for managing hyperkalemia while maintaining or optimizing renin-angiotensin-aldosterone system inhibitor (RAASi) and mineralocorticoid receptor antagonist (MRA) therapy. The series compares oral potassium binders by mechanism of action, onset, tolerability, drug-interaction considerations, and sodium- or volume-related concerns. Faculty also address potassium monitoring, recurrent hyperkalemia, and factors that may influence treatment selection, including edema, CKD severity, diabetes, and concomitant therapies. Evidence from DIAMOND and relevant cardiology and nephrology guidelines is incorporated to support informed potassium binder selection and preservation of kidney- and cardiovascular-protective therapy.

This MinuteCE series examines practical approaches to hyperkalemia management in patients with chronic kidney disease (CKD), heart failure, diabetes, and other cardiorenal comorbidities. Through expert lectures, interviews, and case-based discussions, faculty review guideline-based strategies for managing hyperkalemia while maintaining or optimizing renin-angiotensin-aldosterone system inhibitor (RAASi) and mineralocorticoid receptor antagonist (MRA) therapy. The series compares oral potassium binders by mechanism of action, onset, tolerability, drug-interaction considerations, and sodium- or volume-related concerns. Faculty also address potassium monitoring, recurrent hyperkalemia, and factors that may influence treatment selection, including edema, CKD severity, diabetes, and concomitant therapies. Evidence from DIAMOND and relevant cardiology and nephrology guidelines is incorporated to support informed potassium binder selection and preservation of kidney- and cardiovascular-protective therapy.

This MinuteCE series examines practical approaches to hyperkalemia management in patients with chronic kidney disease (CKD), heart failure, diabetes, and other cardiorenal comorbidities. Through expert lectures, interviews, and case-based discussions, faculty review guideline-based strategies for managing hyperkalemia while maintaining or optimizing renin-angiotensin-aldosterone system inhibitor (RAASi) and mineralocorticoid receptor antagonist (MRA) therapy. The series compares oral potassium binders by mechanism of action, onset, tolerability, drug-interaction considerations, and sodium- or volume-related concerns. Faculty also address potassium monitoring, recurrent hyperkalemia, and factors that may influence treatment selection, including edema, CKD severity, diabetes, and concomitant therapies. Evidence from DIAMOND and relevant cardiology and nephrology guidelines is incorporated to support informed potassium binder selection and preservation of kidney- and cardiovascular-protective therapy.

This MinuteCE series examines practical approaches to hyperkalemia management in patients with chronic kidney disease (CKD), heart failure, diabetes, and other cardiorenal comorbidities. Through expert lectures, interviews, and case-based discussions, faculty review guideline-based strategies for managing hyperkalemia while maintaining or optimizing renin-angiotensin-aldosterone system inhibitor (RAASi) and mineralocorticoid receptor antagonist (MRA) therapy. The series compares oral potassium binders by mechanism of action, onset, tolerability, drug-interaction considerations, and sodium- or volume-related concerns. Faculty also address potassium monitoring, recurrent hyperkalemia, and factors that may influence treatment selection, including edema, CKD severity, diabetes, and concomitant therapies. Evidence from DIAMOND and relevant cardiology and nephrology guidelines is incorporated to support informed potassium binder selection and preservation of kidney- and cardiovascular-protective therapy.

This MinuteCE series examines practical approaches to hyperkalemia management in patients with chronic kidney disease (CKD), heart failure, diabetes, and other cardiorenal comorbidities. Through expert lectures, interviews, and case-based discussions, faculty review guideline-based strategies for managing hyperkalemia while maintaining or optimizing renin-angiotensin-aldosterone system inhibitor (RAASi) and mineralocorticoid receptor antagonist (MRA) therapy. The series compares oral potassium binders by mechanism of action, onset, tolerability, drug-interaction considerations, and sodium- or volume-related concerns. Faculty also address potassium monitoring, recurrent hyperkalemia, and factors that may influence treatment selection, including edema, CKD severity, diabetes, and concomitant therapies. Evidence from DIAMOND and relevant cardiology and nephrology guidelines is incorporated to support informed potassium binder selection and preservation of kidney- and cardiovascular-protective therapy.

This MinuteCE series examines practical approaches to hyperkalemia management in patients with chronic kidney disease (CKD), heart failure, diabetes, and other cardiorenal comorbidities. Through expert lectures, interviews, and case-based discussions, faculty review guideline-based strategies for managing hyperkalemia while maintaining or optimizing renin-angiotensin-aldosterone system inhibitor (RAASi) and mineralocorticoid receptor antagonist (MRA) therapy. The series compares oral potassium binders by mechanism of action, onset, tolerability, drug-interaction considerations, and sodium- or volume-related concerns. Faculty also address potassium monitoring, recurrent hyperkalemia, and factors that may influence treatment selection, including edema, CKD severity, diabetes, and concomitant therapies. Evidence from DIAMOND and relevant cardiology and nephrology guidelines is incorporated to support informed potassium binder selection and preservation of kidney- and cardiovascular-protective therapy.

Although cardiopulmonary exercise testing remains the gold standard for assessing disease progression and guiding advanced heart failure management, the 6-minute walk test plays an important role in evaluating patients in this setting. This simple test provides insight into functional capacity, prognosis, and survival while also helping clinicians monitor treatment response and disease progression. However, adherence to guideline-recommended testing procedures is essential to obtain the most accurate results. In this brief lecture, Dr. Jason Feliberti shares real-world tips for performing the 6-minute walk test and using the results to inform treatment decisions for patients with advanced heart failure.

This comprehensive educational activity focuses on 4 key dimensions of IgA nephropathy (IgAN) management. First, attendees will compare and contrast the mechanisms of action (MOAs) of both approved and investigational IgAN therapies, critically evaluating how each targets specific disease pathways—such as galactose-deficient IgA1 formation, complement activation, and podocyte injury. Second, the program presents a systematic diagnostic approach for confirming suspected IgAN, covering clinical presentation, laboratory workup, urinary biomarkers, and renal biopsy interpretation. Third, participants will evaluate the potential benefits and risks of novel therapies aimed at clinically meaningful proteinuria reduction—including efficacy data, safety considerations, and real-world applicability. Finally, the activity guides clinicians in developing optimized, evidence-based treatment plans that incorporate novel proteinuria-lowering therapies within the broader context of individualized disease management, aligned with current guideline recommendations and patient comorbidities.